Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine

Annals of the Rheumatic Diseases

Volumn 71, Issue 10, 2012, Pages 1630-1635

  Keystone, Edward C ^a   Wang, Millie M ^b   Layton, Mark ^b   Hollis, Sally ^b   McInnes, Iain B ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 9056; C REACTIVE PROTEIN; ETANERCEPT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; PURINERGIC P2X RECEPTOR ANTAGONIST; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2X7 RECEPTOR ANTAGONIST; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ACUTE PHASE RESPONSE; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; INFECTION; JOINT SWELLING; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DISEASE; RHEUMATOID ARTHRITIS; TREATMENT DURATION; VASCULAR DISEASE; VISUAL DISORDER; VOMITING;

ADULT; AGED; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PURINERGIC P2X RECEPTOR ANTAGONISTS; YOUNG ADULT;

EID: 84866105881     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-143578     Document Type: Article

References (11)

1. Braddock M, Quinn A, Canvin J. Therapeutic potential of targeting IL-1 and IL-18 in inflammation. Expert Opin Biol Ther 2004;4:847-60. (Pubitemid 38843222)
2. McInnes IB, Liew FY, Gracie JA. Interleukin-18: a therapeutic target in rheumatoid arthritis? Arthritis Res Ther 2005;7:38-41. (Pubitemid 40214526)
3. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008;118:3537-45.
4. Gabay C, McInnes IB. The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases. Arthritis Res Ther 2009;11:230.
5. Furber M, Alcaraz L, Bent JE, et al. Discovery of potent and selective adamantane-based small-molecule P2X(7) receptor antagonists/interleukin-1beta inhibitors. J Med Chem 2007;50:5882-5.
6. Guile SD, Alcaraz L, Birkinshaw TN, et al. Antagonists of the P2X(7) receptor. From lead identification to drug development. J Med Chem 2009;52:3123-41.
7. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
8. van der Heijde D. How to read radiographs according to the Sharpe/van der Heijde method. J Rheumatol 1999;26:734-5.
9. Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:353-63. (Pubitemid 38198818)
10. 7 receptor attenuates joint destruction in a model of arthritis. Arthritis Rheum 2007;56 (Suppl): S692, abstract 1772.
11. Bevaart L, Vervoordeldonk MJ, Tak PP. Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis? Arthritis Rheum 2010;62:2192-205.